Provisional Agenda

(subject to change)

All times mentioned refer to British Standard Time (BST) – London/GMT +00:00.

World Time Converter: https://www.worldtimebuddy.com

Presentation language: English

Thursday 03rd December 2020 

1155: Welcome and housekeeping

Session 1: Chair  Dr Sylvain Ladame

1200: Dr Guocai Zhong, Peking University Shenzhen Graduate School, Shenzhen, China
An antisense oligonucleotide-regulated RNA switch for controllable gene therapies

1220: Professor Tom Brown (Professor of Chemistry) and Dr Ysobel Baker, Chemistry Research Labs, University of Oxford, and ATDBio Ltd, Oxford, UK
Artificial nucleic acid backbones

1240: Professor Nicolas Winssinger, Department of Organic Chemistry, University of Geneva, Geneva, Switzerland
Converting hybridization into chemical reactions

1300: Dr Aurélie Goyenvalle, Director Laboratory Biothérapies des Maladies Neuromusculaires, UVSQ-INSERM, UFR des sciences de la santé Simone Veil, Université de Versailles Saint Quentin en Yvelines, France
Tricyclo-DNA: promising antisense oligonucleotides for the treatment of neuromuscular and neurodegenerative diseases

1320: Professor Annemieke Aartsma-Rus, Professor of Translational Genetics, Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
Developing an exon skipping therapy for Duchenne muscular dystrophy – you need more than an oligonucleotide

Session 2: Chair  Professor Annemieke Aartsma-Rus

1340: Dr Sara Aguti, UCL Great Ormond Street Institute of Child Health, UK
Exon-skipping oligonucleotides restore functional collagen VI by correcting a common COL6A1 mutation in Ullrich Muscular Dystrophy

1400: Dr Linda Popplewell,Royal Holloway-University of London, London, UK
Development of oligonucleotide therapeutics for various muscular dystrophies 

1420: Dr Alex Garanto, Assistant Professor, Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
Developing of Antisense-based therapies for Stargardt disease

1440: Break (including any breakout rooms)

Session 3: Chair  Dr Mark Edbrooke

1520: Dr Nebojsa Janjic, Chief Science Officer, SomaLogic, Inc, Boulder, CO, USA
Enhancing potency of aptamers through multimerization

1540: Miss Carlota Roca, Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, Barcelona, Spain
Development of DNA aptamers against enzymes of the methylerythritol phosphate pathway

1600: Dr David Evans, Chief Scientific Officer, Sirnaomics, Inc, Cambridge, MA, USA
Novel siRNA constructs containing Gemcitabine to treat cancer

1620: Dr Wesley Abplanalp, Dimmeler Lab, Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe Universitätsklinikum, Frankfurt, Germany
Efficiency and cell type specific target de-repression of antimiR-92a: Results of a first in human study

1640: Dr Simon Richardson, University of Greenwich, Chatham Maritime, Kent, UK
Development of an Exosome-Based siRNA Drug Delivery Platform Modelled on Anthrax Toxin

1700: Dr Sylvain Ladame, Imperial College London, London, UK
Engineering devices for cancer diagnosis based on minimally invasive detection of microRNA biomarkers from bodily fluids

1720: Close